Legal Representation
Attorney
Maury M. Tepper, III
USPTO Deadlines
Next Deadline
42 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2019-08-20)
Due Date
August 20, 2025
Grace Period Ends
February 20, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
30 events| Date | Code | Type | Description |
|---|---|---|---|
| May 7, 2025 | NA75 | E | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED |
| May 7, 2025 | C75A | O | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. |
| May 6, 2025 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Jan 13, 2025 | ES75 | I | TEAS SECTION 71 & 15 RECEIVED |
| Aug 20, 2024 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Jan 3, 2020 | FINV | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Dec 14, 2019 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Dec 13, 2019 | FIMP | P | FINAL DISPOSITION PROCESSED |
| Nov 20, 2019 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Aug 20, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jun 4, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jun 4, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
| May 15, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Apr 26, 2019 | ALIE | A | ASSIGNED TO LIE |
| Apr 16, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Apr 6, 2019 | RFNT | P | REFUSAL PROCESSED BY IB |
| Mar 27, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Mar 27, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Mar 27, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Mar 25, 2019 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Mar 25, 2019 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Mar 21, 2019 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Mar 21, 2019 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Mar 12, 2019 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Mar 12, 2019 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Mar 11, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Mar 10, 2019 | DOCK | D | ASSIGNED TO EXAMINER |
| Mar 7, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 6, 2019 | LIMI | I | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Feb 28, 2019 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 005
[ Anti-infectives; ] anti-inflammatories; [ antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; ] pharmaceutical preparations acting on the central nervous system; [ pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; ] pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, [ the endocrine system, ] * and * the musculo-skeletal system [ and the genitourinary system ] ; [ pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; ] pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders [ ; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma ]
Additional Information
Design Mark
The mark consists of an oval, divided by five lines forming arches of differing heights, around a single line, emanating from the bottom-left of the oval. The arches from right to left are in the colors orange, red, violet and blue with the single line also in blue.
Color Claim
The color(s) orange, red, violet and blue is/are claimed as a feature of the mark.
Classification
International Classes
005